Genentech
Genentech Basket Trial Identifies Impact of Co-Mutations in Dual HER2-Targeted Treatment Response
Researchers studying Perjeta and Herceptin in HER2-positive advanced solid tumors reported that the combination is efficacious in KRAS wild-type tumors.
Blueprint Medicines, Genentech to Discuss With Regulators Gavreto's Activity in RET-Altered Tumors
Updated results from the ARROWÂ trial showed Gavreto's activity in RET fusion-positive solid tumors beyond NSCLC and thyroid cancer.
FDA Expert Panel Votes to Keep Tecentriq Accelerated Approval for Certain Bladder Cancer Patients
The ODAC voted to maintain drug access for patients who can't tolerate chemotherapy until the final overall survival analysis reads out next year in a confirmatory trial.
FDA's ODAC Favors Maintaining Tecentriq Accelerated Approval in Triple-Negative Breast Cancer Subset
The review is part of an industry-wide evaluation of immunotherapies the agency conditionally approved on an accelerated clip.
Researchers used a framework called Trial Pathfinder to show how data-driven eligibility criteria could make trials more inclusive without altering outcomes.Â
Apr 14, 2021